title: Treatment of benign prostatic hyperplasia.
abstract: Lower urinary tract symptoms (LUTS) may be a sign of aging rather than a consequence of benign prostatic enlargement (BPE) or benign prostatic obstruction (BPO). Medical or invasive treatments should address the bothersome symptoms and the quality of life of patients. Alpha blockers and 5-alpha reductase inhibitors are most frequently used in benign prostatic hyperplasia (BPH) medical treatments, whereas Transurethral Resection of the Prostate (TURP) remains the "gold standard" for surgical treatments. Several minimal invasive treatments are emerging with promising outcomes.
authors.affiliation: Saint Louis Hospital, Department of Interventional Radiology, Lisbon, Portugal.
authors.forename: Luís Campos
authors.initials: LC
authors.lastname: Pinheiro
authors.forename: João
authors.initials: J
authors.lastname: Martins Pisco
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D006801:Humans; D053685:Laser Therapy; D008297:Male; D019060:Minimally Invasive Surgical Procedures; D011470:Prostatic Hyperplasia / Q000628:therapy*; D020728:Transurethral Resection of Prostate; D016896:Treatment Outcome
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists